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Available online 15 February 2016Background: Gastrointestinal side effects are particularly common with clozapine and occur with other antipsy-
chotics, ranging from mild constipation to fatal bowel obstruction and/or ischemia. While this adverse-effect
spectrum has been attributed to ‘gastrointestinal hypomotility’, gastrointestinal transit times in antipsychotic-
treated patients have not previously been measured, making this mechanism speculative.
Methods: Using standardized radiopaque marker (‘Metcalf’) methods we established colonic transit times of
antipsychotic-treated psychiatric inpatients and compared themwith population normative values.We analyzed
results by antipsychotic type, antipsychotic dose equivalent, anticholinergic load, duration of treatment, gender,
ethnicity, and age.
Outcomes: For patients not prescribed clozapine, median colonic transit time was 23 h. For patients prescribed
clozapine, median transit time was 104.5 h, over four times longer than those on other antipsychotics or norma-
tive values (p b 0.0001). Eighty percent of clozapine-treated patients had colonic hypomotility, compared with
none of those prescribed other antipsychotics (olanzapine, risperidone, paliperidone aripiprazole, zuclopenthixol
or haloperidol). In the clozapine group, right colon, left colon and rectosigmoid transit times were all markedly
abnormal suggesting pan-colonic pathology. Hypomotility occurred irrespective of gender, age, ethnicity, or
length of clozapine treatment. Transit times were positively correlated with clozapine plasma level (rho =
0.451, p = 0.045), but not with duration of treatment, total antipsychotic load or demographic factors.
Interpretation: Clozapine, unlike the other antipsychotics examined, causesmarked gastrointestinal hypomotility,
as previously hypothesized. Pre-emptive laxative treatment is recommended when starting clozapine.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Gastrointestinal motility1 Search termswere: anti-psychotics, keyword search anti-psychotic* or antipsychotic*,
‘clozapine’ (clozapine.mp OR clozapine/) together with any of the following MESH terms:1. Background
Gastrointestinal side effects are commonwith antipsychotics, partic-
ularly clozapine, ranging in severity from mild constipation to fatal
bowel obstruction and/or ischemia. Constipation is reported in up to
60% of clozapine-treated patients (Hayes and Gibler, 1995) and up to
50% of those receiving other antipsychotics (Ozbilen and Adams,
2009) and is reﬂected in the high utilization of laxative in clozapine-
treated patients (Bailey et al., 2015). The mechanism is considered to
be anticholinergic inhibition of gastrointestinal smoothmuscle contrac-
tion and peristalsis (Ozbilen and Adams, 2009), but serotonin receptor
antagonism likely compounds the problem (Palmer et al., 2008), withtral Regional Forensic Service,
S. Every-Palmer).
. This is an open access article underserotonin playing a crucial role in regulating gastrointestinal motility
(Crowell, 2001). Symptoms of slow transit may include low stool fre-
quency, lack of urge to defecate, abdominal distension, bloating, and
abdominal discomfort (Foxx-Orenstein et al., 2008).
A systematic search of AMED, BIOSIS, CINAHL, EMBASE, MEDLINE,
PsycINFO and PubMed databases with no language restrictions from in-
ception to August 2015 revealed 61 case reports, ﬁve large case series
and one cohort study on the serious or life-threatening clozapine-
induced gastrointestinal effects.1 For every 1000 patients treated withconstipation; intestinal obstruction; gastrointestinal motility; radiopharmaceuticals; di-
gestive system diseases (MEDLINE); digestive system disease (EMBASE); digestive symp-
toms disorders (psycINFO); and related keywords (e.g. bowel; gastric; intestinal; colon*;
digestive; gastrointestinal; or radiopaque and marker*).
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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develop serious gastrointestinal complications (including ileus, bowel
obstruction, bowel ischemia and necrosis) from which one will die.
Pharmacovigilance data shows that amongst antipsychotics, clozapine
has the highest constipation-related mortality. Seventy such deaths
were reported in the USA between 1997 and 2009, with a mortality
rate three times that of clozapine-induced agranulocytosis (De Hert
et al., 2011). A large prospective cohort study showed treatment with
clozapine conferred the greatest risk of fatal ileus compared with
other psychoactive medication (OR: 6.73; 95% CI 1.55–29.17) (Nielsen
and Meyer, 2012).
While these complications have been described as arising from ‘gas-
trointestinal hypomotility’ (Palmer et al., 2008; Flanagan and Ball, 2011;
Nguyen et al., 2014), gastrointestinal transit times in antipsychotic-
treated patients have not beenmeasured previously. There is consensus
that clozapine's effect on gastrointestinal function is important, but
poorly understood and under-researched.2. Objectives
This study sought to ascertain:
- How does colonic transit time (CTT) in antipsychotic-treated inpa-
tients, measured by radiopaque markers (ROMs), compare with
standardized normative values?
- Does CTT differ signiﬁcantly between people treated with clozapine
and treated with other antipsychotics?
- Are other independent variables (including gender, age, ethnicity,
constipation symptoms, antipsychotic load or estimated anticholin-
ergic activity) related to CTT?3. Research Design and Methods
Methods were pre-speciﬁed in the protocol (Every-Palmer et al.,
2013 available at http://hdl.handle.net/10523/6070).3.1. Participants
Participants were inpatients in a New Zealand general and forensic
rehabilitation service. They all received similar diets (hospital meals)
and had similar lifestyles. Recruitment occurred between April 2014
and April 2015.
A-priori power analysis was not conducted given the absence of
earlier investigations.
Eligible participantswere adults (over 18) prescribed antipsychotics
for at least three months and competent to provide informed consent.
Patients prescribed laxatives with a past history of signiﬁcant gastroin-
testinal complications (such as fecal impaction) were excluded because
withholding laxatives (as required for CTT testing) could expose them
to risk.
This study was approved by the New Zealand Health and Disability
Ethics Committee (reference 13/CEN/153).Table 1
Summary of CTT measurement techniques.
Radiopaque markers
Radiation exposure Yes (X-ray) 0.5–0.7 millisieverts
(Wall and Hart, 1997)
Assesses gastric emptying No
Assesses small bowel transit No
Provides segmental colonic transit times Yes
Test location X-ray in local radiology department
Cost Inexpensive (approximately $100)3.2. Measuring Colonic Motility
CTT can be measured using radiopaque markers (ROMs), scintigra-
phy or wireless motility capsules. These methods are summarized in
Table 1.
The conventional, cheapest and most practical way of measur-
ing CTT is with ROMs. This method, used for over 40 years, is the
reference standard in clinical practice (Szarka and Camilleri,
2012) and widely employed in research (Rao et al., 2011). Intra-
and inter-observer reliability are high (Pomerri et al., 2007), with
good correlation (r = 0.7, p b 0.001) between ROM and wireless
motility capsule measurements of CTT in constipated patients
(Rao et al., 2009).
Two main ROMmethods have developed: a single ROM-bolus tech-
nique; and themore sensitivemultiple ROM-bolus (‘Metcalf’) technique
used in this study (Kim and Rhee, 2012). This latter technique involves
ingesting a capsule containing 24 standardized ROMs on three consecu-
tive days with abdominal X-rays on day four and, if necessary, day
seven, quantifying elimination (Metcalf et al., 1987). This method min-
imizes radiation exposure, is reliable, reproducible (Pomerri et al., 2007;
Bouchoucha et al., 1992) and well correlated with stool form in consti-
pated adults (Saad et al., 2010).
Normative data are available for CTT from numerous ROM stud-
ies across different countries (see Table 2). Although none are
from New Zealand, ethnic differences are not marked. Meta-
analysis of relevant international normative data (see Table 1)
gives a population mean CTT of 28.79 h with SD of 18.07 h (n =
304 healthy controls). A CTT 2SD above the population mean (i.e.
N64.9) was pre-speciﬁed as a positive test for colonic hypomotility,
as by convention.
Any prescribed laxatives were temporarily withheld from two days
prior to ROM testing and during the study. Rescue laxatives were avail-
able if participants required them (none did).
On three consecutive days (t= 0 h, t= 24 h, t= 48 h) participants
swallowed a dissolvable gelatin capsule (SITZMARKS®, Konsyl Pharma-
ceuticals Inc.) containing 24 polychlorinated vinylmarkers impregnated
with 33% barium sulfate (4.5 × 1.0 mm). Each day's capsule contained
different shaped markers (Fig. 1).
On day four participants were screened for constipation, ﬁrstly
by being asked if they considered themselves constipated (‘self-re-
ported constipation’), which was intended to mirror normal clini-
cal practice, and secondly by completing a researcher-assisted
questionnaire incorporating all Rome III constipation symptoms
(Table 3) (Longstreth et al., 2006), available on request from the
authors.
At t= 72 h, abdominal X-rays determined ROM location and the
extent of elimination. If over two-thirds (N48) of ROMs remained,
X-rays were repeated at t= 144 h. X-rays were read independently
on an InteleViewer PACS system by SEP and MN. MN was blinded to
independent variables. Vertebral spinous processes demarcated
right and left sides of the colon. The rectosigmoid was deﬁned by
oblique lines between the ﬁfth lumbar vertebra spinous process
and the femoral head. Images were magniﬁed and examined region-
ally and black-white inversion was applied to increase marker
conspicuity.Scintigraphy Wireless motility capsule
Yes (radiolabeled meal) 2.67 millisieverts
(Graff et al., 2001)
No
Yes Yes
Yes Yes
No No
Nuclear medicine department Ambulatory
Moderately expensive (approximately $800) Expensive (over $1000)
Table 2
Colonic transit times in healthy populations).
Study Population Mean age ± SD Mean colon transit time +/−SD (mean + 2SD upper limit) in hours
Right colon Left colon Rectosigmoid colon Total colon
Chaussade et al.
(1986)
Healthy French adults (n = 22)
No demographics given
6.9 ± 8.6 (24) 9.1 ± 10.5 (30) 18.4 ± 12.8 (44) 34.4 ± 16.3 (67)
Kim et al. (2001) Healthy Korean adults (n = 30, males n = 15),
age 43.3 ± 13.2 yrs
Not reported Not reported Not reported 30.3 ± 14.9 (60)
Lee (2010) Healthy Korean adults (n = 35, males = 35),
age 41.9 ± 13.7 yrs
5.4 ± 7.2 (19.8) 7.6 ± 11.0 (29.6) 7.7 ± 12.1 (31.9) 20.5 ± 20.3 (61.1)
Kim et al., (2003) Healthy Korean adults (n = 15, males = 11),
age 50.2 ± 1.5 yrs
6.9 ± 1.2 (9.3) 10.8 ± 2.6 (16) 5.0 ± 1.2 (7.4) 24.0 ± 4.1 (32.2)
Jung et al. (2003) Healthy Korean adults (n = 42, males = 21),
age 34 ± 7 yrs
5.9 ± 6.9 (12.8) 9.2 ± 9.2 (18.4) 11.5 ± 11.1 (22.6) 26.5 ± 19.4 (65.3)
Metcalf et al. (1987) Healthy American adults (n = 73, males = 34)
21 N 40 yrs., 52 b 40 yrs
11.3 ± 10.4 (32) 11.4 ± 13.8 (39) 12.4 ± 11.8 (36) 35 ± 16.5 (68)
Chan et al. (2004) Healthy Chinese adults (n = 51, males = 27)
mean age 42 ± 12 yrs. (30–54)
5.8 ± 5.3 (16) 9.5 ± 10.3 (31) 9.2 ± 11.4 (32) 24.5 ± 18.8 (62)
Robertson et al.
(1993)
Healthy American male adults (n = 16)
age 25 ± 4 yrs. (19–31)
CTT calculated during sedentary week and
non-sedentary week
5.9 ± 6.7 (sedentary)
5.1 ± 8.2
(non-sedentary)
10.3 +/− 14.7
(sedentary)
4.2 ± 4.3
(non-sedentary)
8.3 ± 10 (sedentary)
11.0 ± 11.8
(non-sedentary)
24.5 ± 21.8 (68.1)
(sedentary)
20.4 ± 16.5 (53.4)
(non-sedentary)
Mahassadi et al.
(2003)
Healthy African (Ivorian) adults
(n = 20, males = 16) mean age 25 yrs. (21–38)
8.9 ± 5.8 (20) 12.6 ± 8.3 (29) 14.4 ± 5.45 (25) 34.9 ± 151 (65)
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segmental CTT using the formula: (Metcalf et al., 1987)
Δt ¼ T
N
Xj
i¼1
ni
where Δt=mean transit time, T= time interval between X-rays, N=
number of ingestedmarkers, j=number of X-rays taken, and ni=total
number of markers present on a given ﬁlm sector.
3.3. Other Data Collection
Demographic and clinical information collected included age, gen-
der, ethnicity, BMI, smoking status, medication, diagnoses, serum cloza-
pine levels, medication commencement dates and admission date. Total
antipsychotic load was the sum of all antipsychotic medications
expressed in olanzapine and chlorpromazine equivalents using the
International Consensus Study on Antipsychotic Drug Dosing reference
tables (Gardner et al., 2010).
Anticholinergic load was estimated using the Anticholinergic Drug
Scale (ADS) score; (Carnahan et al., 2006) and an anticholinergic activity
(AA) model was derived from published pharmacokinetic data com-
bined with in-vitro AA to generate AA-dose response curves (Chew
et al., 2006). AA for clozapine, olanzapine, quetiapine, risperidone,
aripiprazole and ziprasidone was estimated from this data, adjusted for
dose, gender and age category (Chew et al., 2006). AA of all other medi-
cations was calculated adjusted for dose, but not gender or age (Chew
et al., 2008). Total AA was a sum of the values ascribed to all medication.Fig. 1. Sitzmarks radiopaque markers3.4. Data Analysis
We used SPSS version-21 (SPSS Inc. Chicago, Illinois, USA). Descrip-
tive statistics (medians with IQR, and plotted distributions of transit
times) provide data summaries for transit times. For demographic and
clinical covariates, continuous variables were compared between med-
ication groups using t-tests for normally distributed variables (age, BMI)
or Mann–Whitney U tests for skewed distribution variables (e.g. anti-
cholinergic load). Categorical covariates were compared using Pearson
chi-squared tests, or Fisher's exact tests when one or more expected
count was less than ﬁve.
Median transit times (with 95% CI) were calculated using Kaplan–
Meier survival analysis, with differences in CTT formally compared
using the log-rank test. Some clozapine-treated patients (n = 8, 40%)
still retained over two-thirds of ROMs at the study's end (t = 144 h).
These CTT values were treated as censored at this time-point. Differ-
ences in transit times by medication group were summarized with
hazard ratios calculated using Cox Proportional-Hazards regression.
These regression analyses did not include adjustment for confounders
(covariates were approximately balanced between groups).
We examined the relationship between CTT and other covariates
such as age, gender, ethnicity, antipsychotic load, anticholinergic bur-
den and diagnosis using Kaplan–Meier survival analysis (with log-
rank tests for statistical signiﬁcance). Within the clozapine group, CTT
was compared with clozapine dose and clozapine serum levels (as sep-
arate analyses) using Cox proportional hazard models; differences in
mean CTT were also examined using linear regression to quantify
mean increase in transit time for a ﬁxed dose/serum level difference be-
tween patients. For these linear regression analyses, CTTs for patients
with incomplete transit were treated as non-censored.: 0-rings; D-rings; and tri-rings.
Table 3
Rome III diagnostic criteria for functional constipation.
Must include two or more of the following
a. Straining during at least 25% of defecations
b. Lumpy or hard stools in at least 25% of defecations
c. Sensation of incomplete evacuation for at least 25% of defecations.
d. Sensation of anorectal obstruction/blockage for at least 25% of defecations.
e. Manual maneuvers to facilitate at least 25% of defecations (e.g. digital evacuation,
support of the pelvic ﬂoor).
f. Fewer than three defecations per week.
128 S. Every-Palmer et al. / EBioMedicine 5 (2016) 125–134While CTTs displayed a skewed distribution, we also calculated
means and standard deviation for comparison with population norma-
tive values.
For hypothesis tests, differences were considered statistically signif-
icant when p b 0.05.
3.5. Funding
Capital and Coast District Health Board provided the research grant
that provided the necessary funding for the ROM studies. The District
Health Board had no role in study design; collection, analysis and inter-
pretation of the data; or in writing or submitting the report for
publication.
4. Results
4.1. Participant Characteristics
Recruitment occurred between 22 April 2014 and 10 April 2015.
There were 61 potentially eligible patients. Six of them (all clozapine-
treated) were excluded due to known gastrointestinal motility prob-
lems. Of the remaining 55 conﬁrmed eligible, 37 (67%) consented to
participate. All 37 participants completed the study and all data were
analyzed. One participant did not complete the ROME III constipation
questionnaire and BMIs were missing for seven participants (three
from the clozapine group and four from the non-clozapine group). Oth-
erwise the data set was complete.
4.2. Demographic Characteristics
The mean age of participants was 39.3 ± 9.8 (SD) years (range 20–
61). Twenty-nine (78.4%) were male. Twenty-three patients (62.2%)
identiﬁed primarily as Māori ethnicity, eight (21.6%) as Paciﬁc Islander
(six Samoan, one Cook Island Māori, one Tokelauan) and six (16.2%)
as New Zealand European (Caucasian).
Most participants (n = 33, 89.2%) had diagnoses of schizophrenia.
Two others had schizoaffective disorder, one bipolar disorder and one
psychosis not otherwise speciﬁed.
4.3. Medication
Antipsychotics: Twenty participants were prescribed clozapine as
their primary antipsychotic (doses ranging from 100 to 750 mg, mean
serumplasma level 489 ng/mL). Of these, forty percent (n=8) received
clozapine as their sole antipsychotic, while the rest also received addi-
tional antipsychotics (clozapine-related data is provided in Table 4).Table 4
Summarized clozapine data for clozapine-treated participants.
Median Mean SEM
Clozapine dose 550 mg 528 mg 36
Clozapine serum level 1457.5 nmol/L (476 ng/mL) 1495 nmol/L (489 ng/mL) 94
Length of time prescribed
clozapine
3 years, 3 months 3 years, 4 months 11.Amongst the 17 participants who were not prescribed clozapine, 14
(82%) received a single antipsychotic and three received two antipsy-
chotics. Antipsychotic regimes are summarized in Table 5 and total
antipsychotic dose equivalents in Table 6.
Laxatives: Eighteen participants had no laxatives in the preceding
month. Half of them had prn (as required) laxatives available, which
had not been utilized. Nineteen participants had used laxatives in the
preceding month, one as a prn and the other 18 regularly. Laxatives
included laxsol (n = 15), polyethylene glycol (n = 6) and lactulose
(n = 3).
Other medications: Participants were prescribed a number of other
medications, most commonly omeprazole (n = 10), metformin (n =
10) and cholecalciferol (n= 8). The cumulative anticholinergic activity
of all medication was accounted for in AA and ADS scores (shown in
Table 6).
4.4. Demographic and Clinical Differences by Clozapine Status
Age, gender and ethnicity were similar in the clozapine and non-
clozapine groups, as were BMI and smoking status (see Table 6). All
clozapine patients had schizophrenia diagnoses (treatment-resistant
schizophrenia is the sole indication for clozapine in New Zealand),
while only 76.5% of non-clozapine patients had this diagnosis.
Clozapine-treated patients received higher antipsychotic doses than
the comparison group (olanzapine clinical daily dose equivalents of
35.8 mg compared with 20.0 mg, SMD 15.8, p= 0.003). Clozapine par-
ticipants also had signiﬁcantly higher estimated total anticholinergic ac-
tivity (median AA = 147.1 compared with 2.0, p b 0.0001), but their
additional anticholinergic burden (i.e. due to medications other than
clozapine) was lower than non-clozapine participants (see Table 6).
Signiﬁcantly more clozapine-treated participants had been pre-
scribed laxatives (pre-emptive laxative treatment is a clinical recom-
mendation for patients starting clozapine within the service). All
laxatives were stopped prior to ROM testing. There was no signiﬁcant
difference between groups in reporting of constipation symptoms, ei-
ther subjective experience of constipation, or ROME III criteria (Table 6).
4.5. Patients Treated on Clozapine had Pronounced Hypomotility
Almost all clozapine users exhibited colonic hypomotility (80%,
deﬁned as CTT N 65 h, 2 SD above the population mean) compared to
no patients (0%) in the non-clozapine group (χ2(1 df) = 20.8,
p b 0.0001). Summary transit time statistics by antipsychotic are
shown in Table 7. Typical day four X-rays from non-clozapine and
clozapine-treated patients appear in Fig. 2.
The non-clozapine group had a median CTT of 23.0 h (95% CI 9.6–
36.5 h). All non-clozapine treated patients had normal CTT (i.e within
2SD of the reference population mean), irrespective of their total anti-
psychotic load (CPZ/OLA equivalents), anticholinergic load or whether
they received monotherapy or polypharmacy.
Colonic transit was over four times longer in the clozapine group
compared with the non-clozapine group (Fig. 3, Table 8; p b 0.0001).
Clozapine patients had a median CTT of 104.5 h (95% CI 73.3–134.7).
Kaplan–Meier survival curves plotting time to elimination by clozapine
status are shown in Fig. 4. The hazard ratio for the difference between
medication groups also indicated a substantially slower rate of elimina-
tion in the clozapine group (HR = 0.04, 95% CI 0.01, 0.17; p b 0.0001).SD Range
mg 161 mg 100-750 mg
nmol/L (31 ng/mL) 419 nmol/L (137 ng/mL) 870–2707 nmol/L (284–885 ng/mL)
5 months 4 years, 3 months 4 months-14.5 years
Table 5
Antipsychotic medication participants were receiving.
Antipsychotic/s prescribed Number
Clozapine group (n = 20) Clozapine monotherapy 8
Clozapine + risperidone 2
Clozapine + aripiprazole 1
Clozapine + aripiprazole + quetiapine 1
Clozapine + haloperidol 1
Clozapine + amisulpride 7
Non-clozapine group (n = 17)
Olanzapine monotherapy 5
Olanzapine + aripiprazole 1
Olanzapine + zuclopenthixol 1
Risperidone monotherapy 6
Risperidone + aripiprazole 1
Aripiprazole monotherapy 2
Haloperidol monotherapy 1
Table 6
Comparison between clozapine and non-clozapine-treated groups.
Variable Clozapine
(n = 20)
Non-clozapine
(n = 17)
Categorical variables Number (%) Number (%) Signiﬁcancea
Gender
Male 14 (70.0%) 15 (88.2%) p= 0.25
Female ratio 6 (30.0%) 2 (11.8%)
Ethnicity
Māori 12 (60%) 11 (64.7%) p= 0.29
Paciﬁc islander 6 (30%) 2 (11.8%)
Pakeha (NZ European) 2 (10%) 4 (23.5%)
Diagnosis
Schizophrenia 20 (100%) 13 (76.5%) p= 0.04
Other diagnosis 0 (0%) 4 (23.5%)
Status
Forensic 10 (50%) 10 (58.8%) p= 0.84
Non-forensic 10 (50%) 7 (41.2%)
Smoking status
Smoker 13 (65%) 9 (52.9%) p= 0.68
Non-smoker 7 (35%) 8 (47.1%)
Constipation
Reports constipation 4 (20.0%) 3 (17.6%) p= 1.00
Denies constipation 16 (80.0%) 14 (82.4%)
Rome III [NB n= 19]
Rome III positive 11 (57.9%) 4 (23.5%) p= 0.08
Rome III negative 8 (42.1%) 13 (76.5%)
Laxatives taken
Regular laxatives 16 (84.2%) 3 (17.6%) p= 0.001
No regular laxatives 4 (22.2%) 14 (82.4%)
Laxatives prescribed
(regular or prn)
Laxatives prescribed 19 (95.0%) 8 (47.1%) p= 0.005
None prescribed 1 (5.0%) 9 (52.9%)
Continuous variables
(parametric)
Mean ± SD Mean ± SD Signiﬁcanceb
BMI (kg/m2) 36.8 ± 9.2 35.9 ± 8.6 p= 0.78
Age (in years) 37.0 ± 8.2 42.0 ± 10.90 p= 0.12
Continuous variables
(non-parametric)
Median (IQR) Mean ± IQR Signiﬁcancec
Chlorpromazine clinical
equivalent dose estimates
1072 (627–1371) 600 (400–650) p= 0.004
Olanzapine clinical
equivalent dose estimates
35.8 (20.9–45.8) 20.0 (13.3–21.7) p= 0.003
Total atropine activity 147.1
(104.0–163.9)
2.0 (0.4–8.4) p b 0.0001
Atropine equivalents with
effect of clozapine removed
0.0 (0.0–1.4) 2.0 (0.4–8.4) p= 0.01
Cholinergic load (ADS) with
effect of clozapine removed
0.0 (0.0–1.8) 1.0 (0.0–2.0) p= 0.44
a Hypothesis tests for categorical variables: chi-squared or Fisher's exact test.
b Hypothesis tests for continuous variables (normally distributed): t-test.
c Hypothesis tests for continuous variables (non-normally distributed):Mann–Whitney
test.
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SD = 42.0) was markedly longer than normal values (SMD = 71.8 h,
p b 0.0001). Right colon, left colon and rectosigmoid transit were all
signiﬁcantly delayed in clozapine-treated patients (Table 8). There
was no signiﬁcant difference (p= 0.72) between CTTs of participants
who received clozapine monotherapy and those who received
clozapine + another antipsychotic (Table 7).
Comparison of CTT by age, gender, smoking status, ethnicity, com-
plaints of constipation or positive ROME III criteria for constipation
showed no signiﬁcant differences in median CTTs (Table 9). Across the
sample, estimated anticholinergic activity and total antipsychotic load
were not signiﬁcant predictors of CTT after controlling for serum cloza-
pine level. Duration of clozapine treatment was not correlated with CTT
(Fig. 5).
Fig. 6 shows CTT plotted against clozapine dose and serum level.
There was a positive correlation between CTT and clozapine dose
(Spearman's rho = 0.31), which was not statistically signiﬁcant (p =
0.165). However, simple correlation does not account for censoring,
and, in this case, will underestimate the magnitude of this relationship.
Using proportional hazard survival analysis (Cox regressionmodel), the
ROM clearance rate decreases by a factor of 0.69 for each 100 mg in-
crease in clozapine dose (HR= 0.685, 95% CI: 0.470–0.999, p=0.049).
Clozapine serum level had a stronger association with CTT than clo-
zapine dose (Spearman's rho= 0.45, p= 0.045). Using Cox regression
analysis, the ROM clearance rate was shown to decrease by a factor of
0.54 for each 250 nmol/L (80 ng/ml) incremental increase in serum
level (HR = 0.539, 95% CI: 0.304–0.953, p= 0.034).
Interestingly, self-reported constipation was a poor predictor of
hypomotility, with a sensitivity of only 25%. Using Rome III criteria
improved sensitivity, but only to 53.3%. Both those clozapine-treated
participants who endorsed and those who denied constipation symp-
toms had hypomotility.
5. Discussion
5.1. Key Results
1. CTTs of clozapine-treated participants were four times longer than
population norms and those on other antipsychotics, with 80% of
clozapine-treated patients exhibiting clear hypomotility.
2. Right colon, left colon and rectosigmoid transit were all abnormal
suggesting pan-colonic hypomotility.
3. Clozapine-treated participants displayed this pattern of hypomotility
independent of age, ethnicity, gender and duration of clozapine
treatment.
4. Higher clozapine serum levels were associated with longer transit
times.
5. In 40% of clozapine-treated patients at least two-thirds of markers
remained in the colon at the study's end (t= 144 h).
6. Subjective reporting of constipation symptoms had low sensitivity in
predicting hypomotility.
7. All non-clozapine-treated participants had transit times within the
normal range.
5.2. Limitations
This study had a number of limitations, enumerated below:
a) Wewere unable to determine the upper bound of CTTs in clozapine-
treated patients. We had not expected such signiﬁcant delays in
transit. We terminated the study at the start of day seven (144 h)
as speciﬁed a-priori, as it was considered against participants' inter-
ests to extend the study and continue withholding laxatives, leading
to censored data for 40% of clozapine treated patients.
b) The ROM technique used does not provide information about gastric
emptying or small bowel transit.
Table 7
Colonic transit times shown by primary antipsychotic.
Antipsychotic Abnormal CTT
test (%)
Mean CTT (95% CI) in hours
Median (95% CI) (IQR) in hours
Median CTT
(days)
Standard mean difference (SMD) with
95% CI compared with population norms)
Clozapine-treated participants
All clozapine n= 20 16 (80%) M= 100.6 (82.1–119.0)
Median = 104.5 (73.3–134.7)
IQR: 66.5–N126.0a
Range: 8·0–N144.0a
4.4 SMD = 71.8 h,
95% CI: 62.6 to 81.0 (p b 0.0001)
Clozapine only antipsychotic
n= 8
Mean clozapine dose = 75 mg (±116)
7 (87.5%) M= 94.1 (62.8–125.5)
Median = 88.0 (56.1–119.9)
IQR: 66.5–N135.0a
Range: 8.0–N144.0a
3.7 SMD = 65.3 h
95% CI: 51.9 to 78.7 (p b 0.0001)
Clozapine augmented
n= 12
Mean clozapine dose = 564 mg (±180)
9 (75%) M= 100.7 (80.7–120.6)
Median = 105.0 (94.8–115.2)
IQR: 55.0–N124.5a
Range: 35.0–N134.0a
4.4 SMD = 71.9,
95% CI: 60.9 to 82.9 (p b 0.0001)
Non-clozapine-treated participants
Aripiprazole
n= 4
0 (0%) M= 28.5 (12.7–4.3)
Median = 24.5 (11.2–34.0)
IQR: 10.0–30.0
Range 14.0–51.0
1.0 SMD =−0.3 h
95% CI:−18.2 to 17.6 (p= 0.97)
Zuclopenthixol
n= 1
0 (0%) 42 1.75 NA
Haloperidol
n= 1
0 (0%) 23 1.0 NA
Olanzapine
n= 7
0 (0%) M= 22.3 (10.7–33.8)
Median = 24.0, (95% CI 0–-62.0)
IQR: 8.0–41.0
Range: 6.0–41.0
1.0 SMD =−6.2 h
95% CI:−20.1 to 7.1 (p= 0.35)
Risperidone (includes LAI risperidone
and paliperidone)
n= 8
0 (0%) M= 20.5, SEM = 5.5, SD = 15.6
Median = 11.0, (5.5–16.5)
IQR: 9.0–30.0
Range: 8.0–52.0
0.5 SMD =−8.3
95% CI:−21.0 to 4.4 (p= 0.20)
a In these cells, more than 25% of the data points were censored, so IQRs and ranges are reported as the time the true 25th centile and upper bound of CTT range respectively must lie
above.
Fig. 2. ROM studies of a non-clozapine and clozapine-treated participant. Typical day four abdominal X-rays from a non-clozapine patient (left) and clozapine (right). The ROMs have
almost all been excreted on the left, whereas on the right in the clozapine-treated patient all 72 ROMs are retained and scattered throughout the bowel in a pattern indicating global
hypomotility.
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Fig. 3. Colonic transit time (in hours) for non-clozapine and clozapine-treated participants.
131S. Every-Palmer et al. / EBioMedicine 5 (2016) 125–134c) We used a summary statistic of normal colonic transit time collated
from other studies for population normative values. New Zealand
reference standards do not exist.
d) Determining patterning of CTT by some variables (e.g gender, eth-
nicity) is hindered by a small sample size and therefore estimates
of differences are imprecise.
e) We could not test CTT of the same patients before and after clozapine
initiation. This would have yielded information about clozapine's
effect on the individuals' gastrointestinal motility.
f) Anticholinergic activity was calculated from standardized dose–re-
sponse tables, not individual receptor assays, giving estimates that
did not account for individual pharmacokinetic variability.5.3. Generalizability
Our participants were physically healthy and psychiatrically stable
forensic and rehabilitation inpatients. They all had similar diets and
lifestyles, reducing confounding, but possibly limiting the potential for
generalization to patients treated in other settings. Patients with
established signiﬁcant hypomotility were excluded (10% of the local
study population), resulting in spectrum bias toward individuals with
serious, but adequately treatedmental illnesswhohad not overtlyman-
ifested gastrointestinal hypomotility.5.4. Interpretation
While it has previously been speculated that clozapine's spectrum of
serious and life-threatening gastrointestinal effects is due to gastroin-
testinal hypomotility (Palmer et al., 2008; Flanagan and Ball, 2011;
Taylor et al., 2015), this study now conﬁrms that such hypomotility
occurs.Table 8
Comparison of segmental transit times for clozapine and non clozapine-treated
participants.
Segment Clozapine group
Median CTT
(95% CI)
Non-clozapine
group Median
CTT (95% CI)
Difference
in medians
Signiﬁcance
(log-rank test)
Right colon 31.0 (14.4–47.6) 8.0 (6.1–9.9) 23.0 p b 0.0001
Left colon 48.0 (15.0–81.0) 6.0 (4.7–7.3) 42.0 p b 0.0001
Rectosigmoid 33.0 (17.9–48.1) 3.0 (1.0–5.0) 30.0 p b 0.0001
Total 104 (73.3–134.7) 23.0 (9.6–36.4) 81.0 p b 0.0001The results of another recent study support our ﬁndings. Baptista et
al (Baptista et al., 2015) gave 137Venezuelan antipsychotic-treated out-
patients a single oral bolus of 25 silver rings (they could not access stan-
dardized ROMs). They considered studies indicative of gastrointestinal
hypomotility if six or more rings remained visible on abdominal X-
rays ﬁve days later, which occurred in 51% of their clozapine group,
compared with 31.3% of those receiving other antipsychotics. No signif-
icant relationship existed between abnormal tests and clozapine treat-
ment duration or dose (serum level was not measured). Similar to our
study, self-reported symptoms were not sensitive in predicting abnor-
mal transit.
Our study found a higher prevalence of clozapine-related
hypomotility (80%), which may relate to methodology, differences in
participant characteristics or to random error. Clozapine serum levels
in our study (mean = 489 ng/mL, SD = 137 ng/mL) were consistent
with recommended levels in the treatment of schizophrenia
(Remington et al., 2013). In the Venezuelan study, clozapine was also
used for indications other than schizophrenia with half the participants
receiving less than 160mg of clozapine. The likely relationship betweenFig. 4. Survival analysis of colonic transit time (in hours) for clozapine and nonclozapine-
treated participants.
Table 9
Relationship between different categorical variables and CTT within clozapine-treated
patients.
Predictor variable Median CTT
(95% CI)
Difference
in medians
Signiﬁcance
(log-rank test)
Smoking status
Non-smoker (n= 7) 126a 35 p= 0.06
Smoker (n= 13) 91 (46.4–135.6)
Gender
Male (n= 14) 105 (94–116) 37 p= 0.45
Female (n= 6) 68 (44–92)
Ethnicity
Caucasian (n= 2) 108.5a 4.5, 14.5 p= 0.90
Māori (n= 12) 104(75–132)
Paciﬁc Islander (n= 6) 94.0a
Constipation?
Yes (n= 4) 104 (60.9–147.1) 13 p= 0.84
No (n= 16) 91 (57.7–124.3
Rome III
Positive (n= 11) 104 (84.6–123.4) 16 p= 0.68
Negative (n= 8) 88 (40.5–135.6)
a In these cases,more than 50% of the data pointswere censored, somedians are reported
as the ﬁgure the true median must lie above and conﬁdence intervals cannot be accurately
calculated.
132 S. Every-Palmer et al. / EBioMedicine 5 (2016) 125–134clozapine dose/serum level and CTT may explain the more severe pa-
thology in our cohort.
The mechanism of clozapine-induced colonic hypomotility remains
to be established, as does clozapine's effects on esophageal, gastric and
small bowel motility. Pre- and post-clozapine comparison of CTTs
would be useful, as would replication of ﬁndings in different popula-
tions. It was surprising that all non-clozapine participants had normal
CTTs. For example, given olanzapine's similar pharmacology and pro-
pensity to cause constipation (Kennedy et al., 2003; Frenchman, 2005;
Kelly et al., 2006), we expected some olanzapine-treated patients to ex-
perience delayed transit.
We also had not anticipated that constipation symptoms,with a sen-
sitivity of 25%, would have such poor predictive validity for colonic
hypomotility. Indeed, half the censored patients, whose CTT extended
beyond the seven-day study period, denied constipation and scored
negatively on the Rome III. This included the most extreme case
where none of the 144 ROMs had even reached the rectosigmoid by
day seven, let alone been excreted. However this participant categori-
cally denied any constipation symptoms and claimed to be passingFig. 5. Colonic transit time plotted by duration of clozapine treatment.regular normal bowelmotions. Similarly, in a series of 102 patients clas-
siﬁed as suffering severe or life-threatening clozapine-induced gastroin-
testinal hypomotility (Palmer et al., 2008), many had not complained of
constipation or other symptoms, but were discovered to have massive
fecal impaction in the operating theater or on autopsy.
The reasons for the disparity between subjective symptoms and
objective pathology are unclear, but are speculated to arise from a com-
bination of reduced pain sensitivity in patients with schizophrenia
(Fishbain, 1982; Rosenthal et al., 1990; Dworkin, 1994; Singh et al.,
2006), difﬁculty in communicating discomfort (Bickerstaff et al., 1988)
and clozapine's sedative and anti-serotonergic properties, which may
reduce intestinal nociception (Palmer et al., 2008). If bowel function is
chronically deranged, the affected individual may also lack a sense of
what is normal. The clinical implications are concerning; the commonly
accepted practice of enquiring whether clozapine treated patients are
constipated has little utility, and may even be misleading. Colonic
hypomotility should be suspected regardless ofwhether gastrointestinal
symptoms are endorsed. Laxatives should be started pre-emptively in
clozapine-treated patients.
Unfortunately there is little evidence on which laxatives are most ef-
fective. There are no high-quality trials on themanagement of clozapine-
induced gastrointestinal hypomotility, and current recommendations
are pragmatic rather than evidence-based (e.g. theMaudsleyGuidelines)
(Taylor et al., 2015). A Cochrane review underway (Every-Palmer et al.,
2014) has not yet identiﬁed any adequate clinical trials on the pharma-
cological treatment of clozapine or other antipsychotic-related constipa-
tion (unpublished data: Every-Palmer et al.). This identiﬁes a signiﬁcant
evidence gap.
In other pharmacologically-related hypomotility disorders such as
opiate-induced constipation, experts and guidelines often advocate for
the ﬁrst-line use of stimulant laxatives (Twycross et al., 2012; Sykes
et al., 2005; Goodheart and Leavitt, 2006). In the general population
there is good evidence for macrogols such as polyethylene glycol
(PEG) in the treatment of constipation (Lee-Robichaud et al., 2010;
Bharucha et al., 2013). Our experience suggests that both senna and
PEG are effective in improving bowel motility in clozapine-treated pa-
tients. To test this hypothesis we are currently conducting a follow up
study re-measuring CTTs once participants are established on laxative
regimes involving these agents.
Other recommended strategies involve using the lowest effective
clozapine dose, with our results showing a positive association between
clozapine plasma level and CTT. Co-prescription of other medications
with known effects on bowel motility (e.g. opiates and anticholinergic
medication) should be avoidedwherever possible. A high degree of vig-
ilance for the emergence of serious gastrointestinal pathology such as
bowel obstruction is mandated. The commonest reported symptoms
heralding such evolution were moderate to severe abdominal pain
and abdominal distension (Palmer et al., 2008). Emergence of these
symptoms in clozapine-treated patients warrants urgent medical refer-
ral and treatment.
Overall clozapine remains an important treatment in psychiatry,
necessitating careful risk–beneﬁt analysis. While gastrointestinal
hypomotility is but one of the drug's considerable adverse effects, cloza-
pine is still the most effective pharmacological agent for otherwise
treatment-resistant schizophrenia, signiﬁcantly improving outcomes
for many patients (Kane et al., 1988) and decreasing overall mortality
due to reduced suicide-rates (Hennen and Baldessarini, 2005; Meltzer
and Okayli, 1995; Walker et al., 1997; Munro et al., 1999).
6. Conclusions
The effect of clozapine on colonic motility is highly signiﬁcant, and
appears to occur regardless of gender, ethnicity, clozapine dose and
duration of treatment.
Our results suggest, counter-intuitively, that when screening for
hypomotility, little is gained by asking clozapine-treated patients
Fig. 6. Colonic transit time plotted by clozapine dose and serum level.
133S. Every-Palmer et al. / EBioMedicine 5 (2016) 125–134about constipation. While important in assessing subjective distress,
constipation symptoms were not sensitive in predicting hypomotility.
This is consistent with many earlier reports where subjects had no
prior complaints until serious pathology emerged.
The results suggest that all clozapine-treated patients are at risk of
gastrointestinal hypomotility, which needs to become part of the con-
sent process. We recommend starting prophylactic laxative treatment
when commencing clozapine in the same way as is recommended for
long-term opioids (Caraceni et al., 2012). Given our observation that
patients prescribed prn (as required) laxatives did not use them, we
suggest prescribing regular laxatives.
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